Oberland Capital agreed to invest up to $400 million into MeiraGTx to support commercialization readiness for its late-stage gene therapy pipeline, including programs previously reacquired from Johnson & Johnson. The financing package includes an initial $135 million from a $10 million equity investment, with additional tranches tied to clinical and regulatory progress. The funding deal signals sustained market confidence in MeiraGTx’s ability to translate platform and late-stage assets into approval and adoption, particularly as gene therapy developers work through payer and manufacturing scale-up challenges. Separately, MeiraGTx also announced a royalty deal with Oberland Capital, structuring cash support around commercialization milestones for two prospects moving toward the market.